Author: Hugh Gosling

A new financial agreement with the UK government will see pharmaceutical companies bring forward payments of around £200 million to help pay for NHS patients’ medicines in 2016.

Nine new medicines were recommended for marketing approval at the last meeting of the of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), bringing the total to 93 for 2015.

Patients with a devastating type of lung cancer have fresh hope after the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Eli Lily’s Portrazza (necitumumab).

Patient satisfaction in NHS hospitals has improved over a nine-year period but only marginally, according to a longitudinal analysis of inpatient survey data.

The EMA is ready to address the challenges ahead, according to the agency’s incoming executive director Professor Guido Rasi, who has outlined his vision for the next five years.